DDInter624 DDInter1477
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Anagrelide
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Fenofibrate
Fenofibrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Efavirenz {u} (Compound) causes {v} (Side Effect) Chest pain
Chest pain {u} (Side Effect) is caused by {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Anagrelide (Compound) and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Efavirenz (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Efavirenz (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Fenofibrate (Compound) and Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Fluvoxamine (Compound) and Fluvoxamine may lead to a major life threatening interaction when taken with Pirfenidone
Efavirenz (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone